Burcon NutraScience Corp.
- WKN: 157793
- ISIN: CA1208311029
- Land: Kanada
Nachricht vom 19.09.2019 | 11:33
Burcon NutraScience Corp.: Burcon Announces Results of Shareholder Meeting
DGAP-News: Burcon NutraScience Corp.
/ Key word(s): AGM/EGM
Burcon Announces Results of Shareholder Meeting
Vancouver, British Columbia, September 18, 2019 - Burcon NutraScience Corporation (TSX: BU) a global technology leader in the development of plant-based proteins, is pleased to announce the results from its 2019 annual meeting of shareholders (the "Meeting") held on September 17, 2019. All of the seven nominees set out in Burcon's management proxy circular dated July 30, 2019 proposed by management for election to the board of directors at the Meeting were elected to the board. Each director elected will hold office until the conclusion of the next annual meeting of shareholders of Burcon or until his or her successor is elected or appointed, unless his or her office is earlier vacated in accordance with Burcon's by-laws or with the provisions of the Business Corporations Act (Yukon).
The results of the voting on the election of the directors are as follows:
Shareholders of the Corporation also approved all other items of business brought forward at the Meeting.
About Burcon NutraScience Corporation
Burcon is a global technology leader in the development of plant-based proteins. The company has developed an extensive portfolio of composition, application, and process patents originating from a core protein extraction and purification technology. Burcon's family of plant proteins includes Peazazz(R), a uniquely soluble and clean-tasting pea protein, Puratein(R), Supertein(R) and Nutratein(R) canola proteins with exceptional functionality and valuable nutritional profiles, and Nutratein-PS(TM) and Nutratein-TZ(TM), Burcon's new pea and canola protein blends that have exceptional functional characteristics, low allergenicity, and a nutritional value exceeding those of standard pea proteins in the market today. Burcon's CLARISOY(R) soy protein - under license to the Archer Daniels Midland Company - offers clarity and high-quality protein nutrition for low-pH beverage systems, and excellent solubility and exceptionally clean flavour at any pH. For more information about the company, visit www.burcon.ca.
The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward- looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding expectations, intentions and plans contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated July 2, 2019 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.
CLARISOY is a trademark of Archer Daniels Midland Company.
Manager, Business Development
Burcon NutraScience Corporation
Tel (604) 733-0896, Toll-free (888) 408-7960
Steve Campbell, APR
Campbell & Company Public Relations
Tel (604) 888-5267
Peazazz and Peazac Pea Proteins FDA GRAS Notified
Burcon NutraScience Corp.: Burcon Announces Re ...
Burcon NutraScience Corp.: Burcon Updates on D ...
Burcon Receives Notice of Allowance from the U ...
BURCON ANNOUNCES APPOINTMENT OF CALVIN CHI L ...
Anleihe im Fokus
"Anleihe - Jetzt zeichnen!"
- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)
Expedeon AG mit attraktiver Produktpipeline
Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.
Der AKTIONÄR News
17. November 09:15 DAX und Co voller Ungewissheit: Kommt nun der Rückschlag? Oder doch ...
17. November 08:15 Global AI Index auf Rekordhoch - so profitieren Anleger vom Megatrend ...
16. November 17:00 Deutsche Rohstoff: Mit 100 Millionen zur Milliarde
16. November 14:08 Amazon, Walt Disney & Co: So geht es weiter
16. November 08:12 Software AG Vorstand im Interview: „Ein gutes Wachstumsrezept“
Conference Call zu den Neunmonatszahlen 2019
15. November 2019
Original-Research: Uzin Utz AG (von Montega AG): Kaufen
15. November 2019